Zobrazeno 1 - 10
of 43
pro vyhledávání: '"Aranzazu Fernandez-Martinez"'
Autor:
Natàlia Lorman-Carbó, Olga Martínez-Sáez, Aranzazu Fernandez-Martinez, Patricia Galván, Nuria Chic, Isabel Garcia-Fructuoso, Adela Rodríguez, Raquel Gómez-Bravo, Francesco Schettini, Paula Blasco, Oleguer Castillo, Blanca González-Farré, Barbara Adamo, Maria Vidal, Montserrat Muñoz, Charles M. Perou, Marcos Malumbres, Joaquín Gavilá, Tomás Pascual, Aleix Prat, Fara Brasó-Maristany
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-10 (2024)
Abstract This study examines the biological effects of palbociclib and ribociclib in hormone receptor-positive breast cancer, pivotal to the HARMONIA prospective phase III clinical trial. We explore the downstream impacts of these CDK4/6 inhibitors,
Externí odkaz:
https://doaj.org/article/ea86ec3e16194f1f8bdd3ad02a335dd9
Autor:
Tomás Pascual, Aranzazu Fernandez-Martinez, Yash Agrawal, Adam D. Pfefferle, Nuria Chic, Fara Brasó-Maristany, Blanca Gonzàlez-Farré, Laia Paré, Guillermo Villacampa, Cristina Saura, Cristina Hernando, Montserrat Muñoz, Patricia Galván, Xavier Gonzàlez-Farré, Mafalda Oliveira, Miguel Gil-Gil, Eva Ciruelos, Patricia Villagrasa, Joaquín Gavilá, Aleix Prat, Charles M. Perou
Publikováno v:
npj Breast Cancer, Vol 10, Iss 1, Pp 1-11 (2024)
Abstract In this study, we performed genomic analyses of cell cycle and tumor microenvironment changes during and after ribociclib and letrozole or chemotherapy in the CORALLEEN trial. 106 women with untreated PAM50-defined Luminal B early breast can
Externí odkaz:
https://doaj.org/article/3f189cf1ef8a4f74a950d11ff22079b9
Autor:
Mattia Rediti, Aranzazu Fernandez-Martinez, David Venet, Françoise Rothé, Katherine A. Hoadley, Joel S. Parker, Baljit Singh, Jordan D. Campbell, Karla V. Ballman, David W. Hillman, Eric P. Winer, Sarra El-Abed, Martine Piccart, Serena Di Cosimo, William Fraser Symmans, Ian E. Krop, Roberto Salgado, Sherene Loi, Lajos Pusztai, Charles M. Perou, Lisa A. Carey, Christos Sotiriou
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-18 (2023)
Abstract The identification of prognostic markers in patients receiving neoadjuvant therapy is crucial for treatment optimization in HER2-positive breast cancer, with the immune microenvironment being a key factor. Here, we investigate the complexity
Externí odkaz:
https://doaj.org/article/14a09996519f49368d11a06978543f0a
Autor:
Tamara Díaz-Redondo, Rocio Lavado-Valenzuela, Begoña Jimenez, Tomas Pascual, Fernando Gálvez, Alejandro Falcón, Maria del Carmen Alamo, Cristina Morales, Marta Amerigo, Javier Pascual, Alfonso Sanchez-Muñoz, Macarena González-Guerrero, Luis Vicioso, Aurora Laborda, Maria Victoria Ortega, Lidia Perez, Aranzazu Fernandez-Martinez, Nuria Chic, Jose Manuel Jerez, Martina Alvarez, Aleix Prat, Nuria Ribelles, Emilio Alba
Publikováno v:
Frontiers in Oncology, Vol 9 (2019)
Background: Double blockade with pertuzumab and trastuzumab combined with chemotherapy is the standard neoadjuvant treatment for HER2-positive early breast cancer. Data derived from clinical trials indicates that the response rates differ among intri
Externí odkaz:
https://doaj.org/article/fe8078c1740f424c8825a31c4ca52cfb
Autor:
Natàlia Lorman-Carbó, Olga Martínez-Sáez, Aranzazu Fernandez-Martinez, Patricia Galván, Nuria Chic, Barbara Adamo, Maria Vidal, Montserrat Muñoz, Charles M. Perou, Joaquín Gavilá, Tomás Pascual, Aleix Prat, Fara Brasó-Maristany
Publikováno v:
Cancer Research. 83:P1-13
Background: Palbociclib might be less effective than ribociclib in HR+/HER2- and HER2-enriched BC. This hypothesis is currently being tested in the HARMONIA prospective phase III clinical trial (NCT05207709). Here, we evaluated the downstream biologi
Autor:
Aleix Prat, Charles M. Perou, Lisa A. Carey, Patricia Galvan, Laia Paré, Benedetta Conte, Mafalda Oliveira, Pierfranco Conte, Antonio Llombart, Gaia Griguolo, Montserrat Muñoz, Barbara Adamo, Maria Vidal, Núria Chic, Patricia Villagrasa, Javier Cortes, Valentina Guarnieri, Joaquin Gavila, Sonia Pernas, M. Vittoria Dieci, Maki Tanioka, Aranzazu Fernandez-Martinez, Tomás Pascual
Supplementary Data
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::31b2c13ec7ed112cb8fdc5f19012162a
https://doi.org/10.1158/1078-0432.22481012
https://doi.org/10.1158/1078-0432.22481012
Autor:
Aleix Prat, Charles M. Perou, Lisa A. Carey, Patricia Galvan, Laia Paré, Benedetta Conte, Mafalda Oliveira, Pierfranco Conte, Antonio Llombart, Gaia Griguolo, Montserrat Muñoz, Barbara Adamo, Maria Vidal, Núria Chic, Patricia Villagrasa, Javier Cortes, Valentina Guarnieri, Joaquin Gavila, Sonia Pernas, M. Vittoria Dieci, Maki Tanioka, Aranzazu Fernandez-Martinez, Tomás Pascual
Purpose:We do not yet have validated biomarkers to predict response and outcome within hormone receptor–positive/HER2-positive (HR+/HER2+) breast cancer. The PAM50-based chemo-endocrine score (CES) predicts chemo-endocrine sensitivity in hormone re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4da9264b9b108c42a6b68680b6fc1c22
https://doi.org/10.1158/1078-0432.c.6530594
https://doi.org/10.1158/1078-0432.c.6530594
Autor:
Jonathan H. Shepherd, Karla Ballman, Mei-Yin C. Polley, Jordan D. Campbell, Cheng Fan, Sara Selitsky, Aranzazu Fernandez-Martinez, Joel S. Parker, Katherine A. Hoadley, Zhiyuan Hu, Yan Li, Matthew G. Soloway, Patricia A. Spears, Baljit Singh, Sara M. Tolaney, George Somlo, Elisa R. Port, Cynthia Ma, Charles Kuzma, Eleftherios Mamounas, Mehra Golshan, Jennifer R. Bellon, Deborah Collyar, Olwen M. Hahn, Clifford A. Hudis, Eric P. Winer, Ann Partridge, Terry Hyslop, Lisa A. Carey, Charles M. Perou, William M. Sikov
Publikováno v:
Journal of Clinical Oncology. 40:1323-1334
PURPOSE CALGB 40603 ( NCT00861705 ), a 2 × 2 randomized phase II trial, demonstrated that adding carboplatin or bevacizumab to weekly paclitaxel (wP) followed by doxorubicin and cyclophosphamide significantly increased the pathologic complete respon
Autor:
Aranzazu Fernandez-Martinez, Tomás Pascual, Baljit Singh, Paolo Nuciforo, Naim U. Rashid, Karla V. Ballman, Jordan D. Campbell, Katherine A. Hoadley, Patricia A. Spears, Laia Pare, Fara Brasó-Maristany, Nuria Chic, Ian Krop, Ann Partridge, Javier Cortés, Antonio Llombart-Cussac, Aleix Prat, Charles M. Perou, Lisa A. Carey
Publikováno v:
Scientia
ImportanceBoth tumor-infiltrating lymphocytes (TILs) assessment and immune-related gene expression signatures by RNA profiling predict higher pathologic complete response (pCR) and improved event-free survival (EFS) in patients with early-stage ERBB2
Autor:
Paola Zagami, Aranzazu Fernandez-Martinez, Naim U. Rashid, Katherine A Hoadley, Patty Spears, Charles M. Perou, Lisa Carey
Publikováno v:
Cancer Research. 83:PD18-04
Background PIK3CA mutations have been described in 20-25% of early-stage HER2-positive breast tumors [1], and are associated with reduced pathologic complete response (pCR) rate after chemotherapy and anti-HER2 agents [2]. However, the independence o